Heavyweight - Century Healthcare completes hundreds of millions of yuan in equity financing-Company News-News

Preface

Recently, Tianjin Century Healthcare Biomedical Engineering Co., Ltd. (hereinafter referred to as "Century Healthcare") announced the completion of billions of yuan in Series A+and Series B financing. The B-round financing is led by Guotou Chuanghe, with investment from institutions such as Yifeng Capital, Dongguan Songshanhu Science City Venture Capital, Xiaochi Capital, and Jinju Investment. The funds raised this time will be used by the company to further accelerate market promotion, consolidate research and development capabilities, and develop new product lines.

1、About us

Century Healthcare was founded in 2008, with its headquarters located in Tianjin. As a national high-tech enterprise, Century Healthcare has obtained Class III medical device registration certificates for multiple ophthalmic products, and has the ability to research and prepare biomaterials - collagen. "Collagen Sponge" has obtained Class III national medical device registration certificates, and there are also multiple biomaterial projects under research.

As one of the earliest manufacturers of artificial lenses in China, Century Healthcare has the ability to develop and produce foldable artificial lenses made of both hydrophilic and hydrophobic materials. Century Healthcare's "pre installed hydrophobic aspherical intraocular lens" was approved in July 23. This product has excellent material performance, compatibility with both hydrophilic and hydrophobic advantages, high implantation efficiency, and adopts a Monte Carlo simulation optimization of -0.1 μ The non spherical design of m is the first in China, with a larger depth of focus range, effectively combating postoperative tilt eccentricity, increasing rotational and axial stability, and providing good clinical feedback. Another type of diffractive multifocal intraocular lens using intelligent light field distribution technology has been clinically enrolled. The product currently has excellent clinical trial data, good visual acuity throughout the entire process, and can meet the needs of elderly people for lens removal. It is expected to be officially launched in 2024.

In the field of optometry, Century Healthcare's defocus lenses, RGP, and hard contact lens care solutions have all been launched and sold. The "Meishiji" multi lens defocus lens adopts Fermat spiral biomimetic technology, achieving an innovative progressive defocus distribution. It can scientifically customize exclusive defocus solutions to meet the personalized needs of children. Century Healthcare also has OK lenses and scleral lenses in its layout in the field of optometry.

From the prevention and control of myopia in adolescents to the treatment of myopia, presbyopia, and cataracts in middle-aged and elderly people, Century Healthcare has made a comprehensive layout and can provide eye health solutions for patients of different age groups.

With the gradual approval of new products, the commercialization process of Century Healthcare continues to accelerate. The deepening of domestic substitution, the implementation of volume based procurement, and the combination of excellent products and excellent teams have quickly established a good reputation for Century Healthcare, with rapid revenue growth and becoming a dark horse in the domestic high-end medical device market.

2、Corporate voice

Pei Xiujuan, founder of Century Healthcare, said:

Thank you very much to new and old investment institutions for their attention and strong support to Century Healthcare. The company has many research pipelines and will launch multiple products every year. Obtaining capital support can effectively promote product research and market expansion, build the company's brand image, assist domestic substitution, and enter the international market. Century Healthcare's vision is to build a first-class research and development production base in the field of ophthalmology, and strive to become a global manufacturer and service technology in the field of ophthalmology "Art provider."

3、Insititutional voice

The Guotou Chuanghe Biomedical Team stated:

Eye diseases are diverse and the patient population is huge. Although competition is fierce, it is a highly distinctive independent track in the medical industry. Century Healthcare has established a dual platform for ophthalmic implantable devices and collagen materials, with coordinated development and a complete innovative ophthalmic optics, materials, and product transformation platform. The core team has been deeply involved in the industry for many years, focusing on research and development, comprehensive layout, strong clinical execution ability, and commercialization experience. Guotou Chuanghe will support the world Century Healthcare has increased its investment in research and development, continued to strengthen its technology and service capabilities, and helped it become an innovative and leading enterprise in the field of ophthalmic medical devices in China, benefiting more ophthalmic patients.

According to Zhu Pai of Yifeng Capital:

As a recognized golden track, ophthalmology has a broad market for therapeutic diseases such as cataracts and myopia prevention and control consumer medicine, which has always been one of Yifeng's key areas of focus. Century Healthcare is one of the few ophthalmic consumables platform enterprises that combines serious medical and consumer medical care. After obtaining certification for a full range of self single focus hydrophilic and hydrophobic intraocular lens products, the product line of artificial lenses continues to expand and enrich, and more single products are about to be launched, including triple focus products in clinical practice Expected to catch up with international giants and fill domestic gaps, the team has strong research and development capabilities, commercialization capabilities, and execution capabilities. In addition, Century Healthcare Optics Pipeline has formed a comprehensive product matrix, and multiple products have been certified and are rapidly progressing in clinical research. At the same time, the company continues to build a biomaterial platform, driving boundary expansion through dual wheel drive. We firmly believe in the team's profound accumulation in the field of ophthalmology and biomaterials, and continue to support the development of Century Healthcare, helping it become a leading enterprise in ophthalmic consumables and biomaterials.

Reprinted on: arterial network official account